title: Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008-2010).
abstract: Since 2008, the French guidelines have promoted the systematic use of 30 mg/day of primaquine for the radical cure of Plasmodium vivax and Plamodium ovale infections. We observed three relapses in 10 patients with P vivax acquired in French Guiana. No relapses were seen in West African P ovale patients.
authors: Infectious and Tropical Diseases Department, Besançon University Hospital, Besançon, France. jffaucher@chubesancon.fr
authors: Jean-François
authors: JF
authors: Faucher
authors: Anne-Pauline
authors: AP
authors: Bellanger
authors: Catherine
authors: C
authors: Chirouze
authors: Laurent
authors: L
authors: Hustache-Mathieu
authors: Sandrine
authors: S
authors: Genton
authors: Bruno
authors: B
authors: Hoen
mesh_terms: D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D004305:Dose-Response Relationship, Drug; D005602:France / Q000453:epidemiology; D006306:Health Surveys; D006801:Humans; D008288:Malaria / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D008297:Male; D008501:Medical Records, Problem-Oriented; D055118:Medication Adherence; D041122:Plasmodium ovale / Q000187:drug effects / Q000302:isolation & purification; D010966:Plasmodium vivax / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D011319:Primaquine / Q000008:administration & dosage / Q000009:adverse effects; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D000962:Antimalarials; D011319:Primaquine